Identification
- Summary
Magnesium trisilicate is an antacid used for the symptomatic treatment of peptic ulcers.
- Brand Names
- Gaviscon Chewable
- Generic Name
- Magnesium trisilicate
- DrugBank Accession Number
- DB09281
- Background
Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Magnesium trisilicate (DB09281)
- Weight
- Average: 260.857
Monoisotopic: 259.86017997 - Chemical Formula
- Mg2O8Si3
- Synonyms
- Magnesio trisilicato
Pharmacology
- Indication
For the treatment of peptic ulcers. Relieving indigestion and heartburn.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Acid reflux Combination Product in combination with: Simethicone (DB09512), Aluminum hydroxide (DB06723) ••• ••• •••••• Used in combination to treat Acid indigestion Combination Product in combination with: Aluminum hydroxide (DB06723) ••• ••• Used in combination to treat Bloating Combination Product in combination with: Simethicone (DB09512), Aluminum hydroxide (DB06723) ••• ••• •••••• Used in combination to treat Colic Combination Product in combination with: Aluminum hydroxide (DB06723), Simethicone (DB09512) ••• ••• •••••• Used in combination to treat Flatulence Combination Product in combination with: Simethicone (DB09512), Aluminum hydroxide (DB06723) ••• ••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Magnesium trisilicate works by increasing the pH of gastric juice via a neutralisation reaction. It also precipitates colloidal silica, which can coat gastrointestinal mucosa conferring further protection.
- Mechanism of action
The gelatinous silicon dioxide, formed by the reaction of magnesium trisilicate with gastric contents is said to protect ulcerated mucosal surfaces and favor healing.
- Absorption
The hydrated silicon dioxide formed in the stomach and passes into the intestinal track where, silica can be partly absorbed.
- Volume of distribution
The hydrated silicon dioxide formed in the stomach and passes into the intestinal track.
- Protein binding
33%
- Metabolism
- Not Available
- Route of elimination
Excreted in the urine.
- Half-life
16-20 hours
- Clearance
Maximum magnesium clearance is directly proportional to creatinine clearance.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Adequate doses of magnesium trisilicate may cause diarrhea due to the action of soluble magnesium salts in the enteric tract. Approx 5% of the magnesium is absorbed.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. Acetaminophen Magnesium trisilicate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. Acetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Magnesium trisilicate. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Magnesium trisilicate hydrate C2E1CI501T 39365-87-2 FSBVERYRVPGNGG-UHFFFAOYSA-N - Active Moieties
Name Kind UNII CAS InChI Key Magnesium cation ionic T6V3LHY838 22537-22-0 JLVVSXFLKOJNIY-UHFFFAOYSA-N - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Virus Blocker Cl-40 Stick 80 g/100g Topical JOONGWAN LIFE & STYLE Co.ltd 2020-10-31 Not applicable US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AIRTAB Magnesium trisilicate (350 MG) + Aluminum hydroxide (250 MG) Tablet Oral บริษัท มิลลิเมด จำกัด จำกัด 2003-07-17 Not applicable Thailand 
Alka Phenyl Tab Magnesium trisilicate (150 mg / tab) + Aluminum hydroxide (100 mg / tab) + Phenylbutazone (100 mg / tab) Tablet Oral Duchesnay Inc. 1978-12-31 1997-08-11 Canada 
Alka Phenylbutazone Tab Magnesium trisilicate (150 mg / tab) + Aluminum hydroxide (100 mg / tab) + Phenylbutazone (100 mg / tab) Tablet Oral Pro Doc Limitee 1974-12-31 1997-08-14 Canada ALLUMAG M TABLET Magnesium trisilicate (250 mg) + Aluminum hydroxide (120 mg) Tablet Oral CHULIA PHARMA SDN BHD 2017-10-03 2019-09-11 Malaysia 
ALLUMAG M TABLET Magnesium trisilicate (250 mg) + Aluminum hydroxide (120 mg) Tablet Oral PHARMATECH RESOURCES (FE) PTE. LTD. 1997-09-25 Not applicable Singapore 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Virus Blocker Cl-40 Magnesium trisilicate hydrate (80 g/100g) Stick Topical JOONGWAN LIFE & STYLE Co.ltd 2020-10-31 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkaline earth metal silicates. These are inorganic compounds in which the largest oxoanion is silicate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkaline earth metal oxoanionic compounds
- Sub Class
- Alkaline earth metal silicates
- Direct Parent
- Alkaline earth metal silicates
- Alternative Parents
- Miscellaneous silicates / Metalloid salts / Inorganic salts / Inorganic oxides
- Substituents
- Alkaline earth metal silicate / Inorganic metalloid salt / Inorganic oxide / Inorganic salt / Silicate
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FML8G1U0Y3
- CAS number
- 14987-04-3
- InChI Key
- GXGAKHNRMVGRPK-UHFFFAOYSA-N
- InChI
- InChI=1S/2Mg.O8Si3/c;;1-9(2)7-11(5,6)8-10(3)4/q2*+2;-4
- IUPAC Name
- dimagnesium(2+) ion {[dioxido({[oxido(oxo)silyl]oxy})silyl]oxy}silanoylolate
- SMILES
- [Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
References
- General References
- External Links
- KEGG Drug
- D03271
- PubChem Compound
- 5311266
- PubChem Substance
- 310265174
- ChemSpider
- 4470779
- 29170
- ChEMBL
- CHEMBL2096633
- Wikipedia
- Magnesium_trisilicate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Gastro-esophageal Reflux Disease (GERD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 120 mg Tablet Oral 300 mg Suspension Oral Tablet Tablet Oral Suspension Oral 50 mg/ml Tablet, chewable Oral Solution Oral Suspension Suspension Oral 400 mg/5ml Tablet Oral 250 mg Stick Topical 80 g/100g Tablet Oral 200 mg Capsule Powder - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -2.7 Chemaxon pKa (Strongest Acidic) 2.65 Chemaxon pKa (Strongest Basic) -7.7 Chemaxon Physiological Charge -4 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 144.84 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 11.36 m3·mol-1 Chemaxon Polarizability 11.91 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0bt9-0090000000-d17f8b11fa8fb9b185d2 - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at October 29, 2015 15:58 / Updated at June 12, 2020 16:52